IDEAYA Biosciences Inc. (IDYA)
IDEAYA Biosciences Statistics
Share Statistics
IDEAYA Biosciences has 87.54M shares outstanding. The number of shares has increased by 15.92% in one year.
| Shares Outstanding | 87.54M |
| Shares Change (YoY) | 15.92% |
| Shares Change (QoQ) | 2.31% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 80.84M |
| Failed to Deliver (FTD) Shares | 959 |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 9.67M, so 11.19% of the outstanding shares have been sold short.
| Short Interest | 9.67M |
| Short % of Shares Out | 11.19% |
| Short % of Float | 12.49% |
| Short Ratio (days to cover) | 10.55 |
Valuation Ratios
The PE ratio is -7.65 and the forward PE ratio is -8.81. IDEAYA Biosciences's PEG ratio is -0.11.
| PE Ratio | -7.65 |
| Forward PE | -8.81 |
| PS Ratio | 299.88 |
| Forward PS | 2.4 |
| PB Ratio | 1.98 |
| P/FCF Ratio | -8.35 |
| PEG Ratio | -0.11 |
Enterprise Valuation
IDEAYA Biosciences Inc. has an Enterprise Value (EV) of 1.89B.
| EV / Earnings | -6.89 |
| EV / Sales | 270.34 |
| EV / EBITDA | -5.79 |
| EV / EBIT | -5.79 |
| EV / FCF | -7.53 |
Financial Position
The company has a current ratio of 14.97, with a Debt / Equity ratio of 0.02.
| Current Ratio | 14.97 |
| Quick Ratio | 14.97 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.78 |
| Cash Flow / Debt | -12.91 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.26% and return on capital (ROIC) is -30.32%.
| Return on Equity (ROE) | -0.26% |
| Return on Assets (ROA) | -0.24% |
| Return on Capital (ROIC) | -30.32% |
| Revenue Per Employee | $53,435.11 |
| Profits Per Employee | $-2,095,244.27 |
| Employee Count | 131 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -60.3% in the last 52 weeks. The beta is 0.75, so IDEAYA Biosciences's price volatility has been higher than the market average.
| Beta | 0.75 |
| 52-Week Price Change | -60.3% |
| 50-Day Moving Average | 20.96 |
| 200-Day Moving Average | 30.01 |
| Relative Strength Index (RSI) | 33.91 |
| Average Volume (20 Days) | 893.4K |
Income Statement
In the last 12 months, IDEAYA Biosciences had revenue of 7M and earned -274.48M in profits. Earnings per share was -3.36.
| Revenue | 7M |
| Gross Profit | 7M |
| Operating Income | -326.98M |
| Net Income | -274.48M |
| EBITDA | -326.98M |
| EBIT | -326.98M |
| Earnings Per Share (EPS) | -3.36 |
Balance Sheet
The company has 84.38M in cash and 19.17M in debt, giving a net cash position of 65.21M.
| Cash & Cash Equivalents | 84.38M |
| Total Debt | 19.17M |
| Net Cash | 65.21M |
| Retained Earnings | -622.84M |
| Total Assets | 1.12B |
| Working Capital | 643.64M |
Cash Flow
In the last 12 months, operating cash flow was -247.58M and capital expenditures -3.86M, giving a free cash flow of -251.44M.
| Operating Cash Flow | -247.58M |
| Capital Expenditures | -3.86M |
| Free Cash Flow | -251.44M |
| FCF Per Share | -3.08 |
Margins
Gross margin is 100%, with operating and profit margins of -4.67K% and -3.92K%.
| Gross Margin | 100% |
| Operating Margin | -4.67K% |
| Pretax Margin | -3.92K% |
| Profit Margin | -3.92K% |
| EBITDA Margin | -4.67K% |
| EBIT Margin | -4.67K% |
| FCF Margin | -3.59K% |
Dividends & Yields
IDYA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -19.29% |
| FCF Yield | -16.49% |
Analyst Forecast
The average price target for IDYA is $53, which is 204.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $53 |
| Price Target Difference | 204.2% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 13.52 |
| Piotroski F-Score | 2 |